Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | APEX nuclease (multifunctional DNA repair enzyme) 1 | Starlite/ChEMBL | No references |
Homo sapiens | glutaminase | Starlite/ChEMBL | No references |
Homo sapiens | microtubule-associated protein tau | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.0279 | 0.3167 | 0.8352 |
Loa Loa (eye worm) | calcium/calmodulin-stimulated cyclic nucleotide phosphodiesterase | 0.0302 | 0.3446 | 0.9086 |
Loa Loa (eye worm) | hypothetical protein | 0.0302 | 0.3446 | 0.9086 |
Loa Loa (eye worm) | hypothetical protein | 0.0279 | 0.3167 | 0.8352 |
Leishmania major | apurinic/apyrimidinic endonuclease-redox protein | 0.0023 | 0 | 0.5 |
Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.0023 | 0 | 0.5 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease | 0.0023 | 0 | 0.5 |
Schistosoma mansoni | microtubule-associated protein tau | 0.0833 | 1 | 1 |
Loa Loa (eye worm) | glutaminase 2 | 0.033 | 0.3792 | 1 |
Brugia malayi | glutaminase DH11.1 | 0.033 | 0.3792 | 1 |
Mycobacterium ulcerans | glutaminase | 0.033 | 0.3792 | 1 |
Brugia malayi | 3'5'-cyclic nucleotide phosphodiesterase family protein | 0.0302 | 0.3446 | 0.9086 |
Echinococcus multilocularis | microtubule associated protein 2 | 0.0833 | 1 | 1 |
Entamoeba histolytica | exodeoxyribonuclease III, putative | 0.0023 | 0 | 0.5 |
Loa Loa (eye worm) | glutaminase | 0.033 | 0.3792 | 1 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0023 | 0 | 0.5 |
Plasmodium vivax | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0023 | 0 | 0.5 |
Plasmodium falciparum | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0023 | 0 | 0.5 |
Trichomonas vaginalis | glutaminase, putative | 0.033 | 0.3792 | 1 |
Trypanosoma brucei | apurinic/apyrimidinic endonuclease, putative | 0.0023 | 0 | 0.5 |
Schistosoma mansoni | glutaminase | 0.033 | 0.3792 | 0.3792 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.0023 | 0 | 0.5 |
Toxoplasma gondii | exonuclease III APE | 0.0023 | 0 | 0.5 |
Schistosoma mansoni | camp-specific cyclic nucleotide phosphodiesterase | 0.0302 | 0.3446 | 0.3446 |
Loa Loa (eye worm) | hypothetical protein | 0.0279 | 0.3167 | 0.8352 |
Giardia lamblia | Endonuclease/Exonuclease/phosphatase | 0.0023 | 0 | 0.5 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease, putative | 0.0023 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.1995 uM | PubChem BioAssay. qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 5.6234 uM | PubChem BioAssay. qHTS for Inhibitors of Glutaminase (GLS). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (binding) | = 15.8489 um | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding. (Class of assay: confirmatory) [Related pubchem assays: 596 ] | ChEMBL. | No reference |
Potency (functional) | = 44.6684 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1). (Class of assay: confirmatory) [Related pubchem assays: 1030 (qHTS Validation Assay for Inhibitors of aldehyde dehydrogenase 1 (ALDH1A1))] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.